Is Dulaglutide the Same as Semaglutide?

You've seen both names on a forum, here's why they keep appearing together

The scenario plays out regularly: someone researching weight-loss injections reads about semaglutide, then stumbles across dulaglutide in the same thread, and wonders whether the two are interchangeable. A question our prescribers hear most weeks, in some form or another. The honest answer is that the confusion is understandable but the medicines are meaningfully different, even if their family resemblance is real.

Both dulaglutide and semaglutide mimic a gut hormone called GLP-1, which signals fullness to the brain and slows the rate at which the stomach empties. That shared mechanism is why both reduce blood sugar in people with type 2 diabetes and why both tend to reduce appetite as a side effect. For a detailed look at the broader GLP-1 family and where semaglutide fits within it, the relationship between GLP-1 and semaglutide is worth reading. But sharing a receptor target is a bit like two antibiotics sharing a target bacteria, similar enough to be cousins, different enough to have distinct clinical profiles, different trial data, and different regulatory approvals.

Dulaglutide is sold as Trulicity by Eli Lilly. Semaglutide is sold as Wegovy (for weight management) and Ozempic (for type 2 diabetes) by Novo Nordisk. The molecular structures diverge in how they are fused to carrier proteins, which affects how long each stays active in the body and how they are absorbed.

The licence gap is the part that matters most

In the UK, medicines are approved for specific indications by the MHRA. Dulaglutide holds a licence for type 2 diabetes. Full stop. The NHS medicines information for semaglutide makes clear that semaglutide, by contrast, holds licences both for type 2 diabetes (Ozempic) and for weight management in adults without diabetes (Wegovy). Prescribing a medicine outside its licensed indication is possible in limited clinical circumstances, but it requires explicit clinical justification and is not standard practice for weight management.

This matters for anyone asking whether semaglutide is the same as dulaglutide in the hope of accessing weight-loss treatment. Dulaglutide simply is not available on a weight-management pathway. A prescriber offering it for weight loss without a licensed basis would be stepping well outside standard practice. Semaglutide as Wegovy, on the other hand, went through dedicated weight-management trials (the STEP programme) and the results were sufficient for both MHRA licensing and a NICE technology appraisal. NICE recommends semaglutide for weight management under specific criteria, including BMI and the involvement of a specialist service, as set out in NICE's appraisal of semaglutide (TA875).

If you want to understand how Wegovy specifically relates to the semaglutide molecule, the page on whether semaglutide and Wegovy are the same thing covers that clearly.

How the side-effect profiles compare, and where they diverge

Because both medicines work through GLP-1 receptors, the side-effect terrain overlaps considerably. Nausea, loose stools, constipation, indigestion, and reduced appetite appear in trial populations for both. Injection-site reactions are common to all subcutaneous GLP-1 medicines. The intensity and frequency vary between individuals and between doses, but the general pattern is a GI-heavy early phase that tends to settle as the body adjusts.

Where they diverge: the cardiovascular trial data, the weight-loss evidence, and the approved dose ceilings are all different. Semaglutide at the 2.4 mg Wegovy maintenance dose produced around 15% average weight reduction over 68 weeks in the STEP 1 trial. Dulaglutide's trials were not designed around weight loss as a primary endpoint, so no equivalent weight-management figure exists. Comparing them on that basis is not straightforward. For a side-by-side look at dulaglutide and semaglutide with more detail on the clinical differences, the dedicated comparison of dulaglutide and semaglutide goes further.

Liraglutide is another GLP-1 medicine that sometimes enters these comparisons. If you have seen it mentioned alongside semaglutide, the page on liraglutide versus semaglutide covers what they share and where they part ways.

What this means if you are considering weight management treatment

The practical upshot is straightforward. If weight management is your goal, semaglutide as Wegovy is the GLP-1 medicine with a UK weight-loss licence, robust trial data, and a NICE appraisal behind it. Dulaglutide is not part of that pathway. You can read a full overview of what semaglutide is and how it works as a starting point, or go straight to the weight-loss treatment overview if you want to see the broader options available.

Private access to Wegovy through a regulated service does not require a waiting list or a GP referral, it does require a clinical assessment by a prescriber who can confirm suitability. At nume, that review is carried out by a GPhC-registered Independent Prescriber on the day your consultation is submitted. Our pharmacy is registered with the GPhC (registration number 9012878), verifiable directly at the GPhC register. If you would like to explore whether Wegovy is clinically appropriate for you, start your free consultation and a prescriber will review your answers the same day.